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008, the DPT dropout rate in Kabarole was high (18%). This
tudy assessed the service, community and individual factors
ssociated with DPT1-3 dropout in Kabarole District.
Methods: A cross sectional study using cluster sampling
as employed. Two clusters at parish level (rural and urban)
ach from a county in the district were selected by sim-
le random sampling and all villages therein were studied.
total of 230 children (115 from either cluster) were
ecruited and their parent or guardian interviewed. Cross-
abulations and chi-square tests were used to determine the
trength of associations between independent variables and
he outcome. Binary logistic regression was done to adjust
or potential confounders and identify independent predic-
ors. Key informant interviews were held with in-charges of
ealth units. Qualitative data was analysed manually using
hematic approach and results presented in the form of text.
Results: Factors found to be associated with DPT1-3
ropout were; lack of caretaker knowledge about DPT
osage, (adj. OR = 8.2; 95% CI: 3.12, 21.53); Child’s Birth
rder, 6th and above (adj. OR = 3.0; 95% CI: 0.80, 11.05);
hild Birth Order 2-3 (adj. OR = 2.2; 95% CI: 0.70, 6.71);
hild age group 31-36 compared to 12-18 (adj. OR = 2.5; 95%
I: 0.81, 7.84). However, Rural residence (OR = 1.2; 95% CI:
.56, 2.57); and Child without immunisation card (OR = 4.4;
5% CI: 0.35, 39.86) were not signiﬁcantly associated with
PT dropout.
Conclusion: The current DPT1-3 dropout prevalence in
abarole is still high but dropping (13.7%). DPT 1-3 dropout
s associated with caretaker lack of knowledge of number of
osages a child should receive and involvement of religious
eaders, long travel distance to point of accessing trans-
ort means, and convenient time for immunisation. Findings
rom this study can be used to improve DPT immunisation
ervices. Speciﬁc campaigns on DPT immunisation through
ome visits, involving community leaders and full day immu-
isation can help further reduce the dropout rate.
oi:10.1016/j.ijid.2010.02.626
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Background: In a clinical trial in ambulatory older adults,
st and 2nd PN23 doses induced signiﬁcant increases in IgG
ntibody and were generally well tolerated. We re-enrolled
rial participants to study 10-year antibody persistence fol-
owing the earlier doses, and immunogenicity and safety of
nd or 3rd PN23 doses.Methods: Ten years after receiving a 1st or 2nd PN23
ose, 143 trial participants (age 60-93 years, median 77)
ere re-enrolled and revaccinated (2nd dose n = 72, 3rd dose
= 71). Sera obtained before and 30 days postvaccination
r
l
t
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ere analyzed by ELISA for IgG to vaccine serotypes 3, 4,
B, 8, 9 V, 12F, 14, and 23F. Participants recorded all adverse
xperiences (AEs) through 14 days postvaccination. Serious
Es were monitored through 30 days postvaccination.
Results: Ten years postvaccination, geometric mean con-
entrations (GMCs) in 1st- and 2nddose recipients remained
igher than prevaccination GMCs in 1st-dose subjects (when
hey were vaccine-naive) for all but serotype 3. Second
nd 3rd doses induced signiﬁcant increases in GMCs for
and 6 serotypes, respectively; GMCs for all 8 serotypes
ncreased in participants < and ‘‘75 years old. Frequencies
f injection-site and systemic AEs were lower after the 2nd
han the 3rd dose. Among 3rd-dose recipients, injection-site
ain, swelling, and redness were reported by 75%, 39%, and
0%, respectively, while fatigue, body aches, and headache
ere reported by 38%, 34%, and 25%, respectively. Fever
oral temperature ‘‘100 ◦F [37.8 ◦C]) occurred in 0% and 6%
f 2nd- and 3rd-dose recipients, respectively; the maxi-
um reported temperature was 100.2 ◦F (37.9 ◦C). AEs after
ither dose were generally mild, and > 90% resolved within
week. No vaccine-related serious AEs were reported.
Conclusion: Although protective levels have not been
stablished for adults, antipneumococcal antibody is known
o protect against pneumococcal disease. In ambulatory
lder adults, 1st and 2nd PN23 doses induced IgG antibody to
accine serotypes which still exceeded vaccine-naive levels
fter 10 years. Moreover, 2nd and 3rd doses administered 10
ears after the previous dose were immunogenic and gen-
rally well tolerated in those < and ‘‘75 years old. These
ndings are consistent with a beneﬁcial effect of 1st, 2nd,
nd 3rd PN23 doses.
oi:10.1016/j.ijid.2010.02.627
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Background: Argentine has been polio free since 1984 and
as a sustained and active surveillance of the acute ﬂaccid
aralysis (AFP) that involves an epidemiology and laboratory
pproach, reaching all the PAHO indicators. In this context
e describe the emergence of a case of AFP due to an VDPV
n a 15-months old boy with polyclonal agammaglobuline-
ia.
Methods: The case was notiﬁed to the National Program,
nd a stool sample and a throat swab were sent to the
egional Reference Center for Polio Diagnosis. Samples were
noculated in Rd and L20B cells following the new algorithm
ecommended by WHO. In less than 2 days a virus was iso-
ated in both samples which were characterized as a polio
ype 1. They were sequenced in the VP1 region, 5ˇıNCR. As
result we found a 3,7% (stool sample) and 3,5% (throat
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swab) nucleotide difference in VP1 compared with the Sabin
strain. These results conﬁrm the presence of an iVDPV1. The
sequences of 5ˇıNCR showed the 480 nucleotide change, prov-
ing the reversion of the sabin strain to the infectivity. These
ﬁndings were sent to the National Program in less than 15
days.
Results: After the detection of AFP notiﬁcation was sent
to the ﬁeld, Epidemiology actions were made as in all cases.
In the investigation three different locations were estab-
lished as the child residence. All of them were visited and
vaccination of all children under 18 years old was done. A
national and international alert were sent Active community
surveillance was made and contact and environmental sam-
ples were collected and sent to the Regional Lab. In none
of them the iVDPV 1 was detected. Four serial samples from
the case were taken each month, in all of them the same
iVDPV1 was isolated.
Conclusion: The country has sustained the surveillance
of AFP through 22 years based on the collaborative work
between the laboratory and the epidemiologists. No other
cases appeared although the vaccine coverage in one of
the district was very low. As consequence of this ﬁnd-
ing a national vaccination campaign was made. Although
poliomyelitis is a threat to the region Argentine is ready to
face it.
doi:10.1016/j.ijid.2010.02.628
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8 Administración Nacional de Medicamentos, Alimentos y
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Background: The acronym ESAVI deﬁnes any clinical pic-
ture after vaccination chronologically related to its use.
Further analysis of the event determines the role of the
vaccine in its causality. In the case of YFV, three cate-
gories of severe adverse events are described: anaphylactic
reactions, YF neurotropic disease (YFV-AND), viscerotropic
disease (YFV-AVD). YFV is included in Argentinaˇıs national
immunization program for use in population older than
one year of age in regions with transmission risk. It is
also prescribed to travelers to endemic zones and can be
required upon International Health Regulation allowance.
We describe the clinical, epidemiological and laboratory
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roﬁle of ESAVIs in the context of an extraordinarily
ncreased YFV administration in Argentina in 2008, due to
eported fatal cases involving humans and monkeys in risk
ones.
Methods: This is a descriptive study encompassing the
eriod between January and December, 2008. Complete
FV-ESAVI forms were included, after the expert commit-
ee evaluations. Adverse events were grouped using current
AHO/WHO classiﬁcation. Samples (serum, CSF and liver
iopsies) were processed at the INEVH through standard
echniques.
Vaccine shots: 1,806,400.
Results: Fifty ESAVIs were included:
lassiﬁcation Mild-Moderate Severe
12 2
a - -
b 23 9
- 1
The 2b severe ESAVIs consisted of eight YFV-AND and one
FV-VD, whereas the two severe type 1 ESAVIs consisted of
ne urinary sepsis and a sepsis-like case without ﬁnal diag-
osis. The type 3 ESAVI was an ADEM.
Neither reactions nor programmatic errors were
eported.
YFV-VD rate was 0.5/1.000.000 doses; YFV-AND
.4/1.000.000 doses No particular vaccine lot was
elated to ESAVIs. Global incidence of ESAVIs coincides
ith the heretofore published data. However, some of
he authors knew of more clinically compatible YFV-AND
nd VD non-studied cases, and there is strong suspicion of
nderreporting.
Conclusion: An accurate surveillance system and a refer-
nce laboratory are fundamental for ESAVIs study. Detailed
eports for valid conclusions and opportune actions, plus
multidisciplinary work for rigorous analysis is needed.
carefully managed risk-beneﬁt balance when prescribing
FV alongside with updated epidemiological information for
ccurate guidance is critical.
oi:10.1016/j.ijid.2010.02.629
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Background: BCG vaccine is the only preventive measure
gainst tuberculosis. At least two genomes from BCG, Pas-
eur and Japan, have been described. Evolutionary schemes
stablish by DU2 and other markers situated BCG Japan and
asteur into group I and IV from genealogy of BCG vac-
ines, respectively, classiﬁed as early and late strains. Some
CG such as Mexico 1931 is not included in any comparative
tudies based on phenotypic, genotyping, immune response
